NVCR News & Events

Novocure announced positive results today from the Phase 2 PANOVA-4 trial of Tumor Treating Fields, TTFields, therapy concomitant with atezolizumab, gemcitabine and nab-paclitaxel as a first-line treatment for metastatic pancreatic ductal adenocarcinoma, mPDAC. PANOVA-4 met its pre-specified primary endpoint, achieving a statistically significant improvement in disease control rate, DCR, compared to the DCR reported in the Phase 3 MPACT study used as the historical control. The DCR in patients treated with TTFields therapy concomitantly with atezolizumab and gem/nab-pac was 74.4% compared to a DCR of 48% in patients receiving gem/nab-pac alone in the historical control. Secondary endpoints in PANOVA-4 include objective response rate and overall survival. The ORR in patients treated with TTFields therapy concomitantly with atezolizumab and gem/nab-pac was 34.6% and median OS was 9.7 months. Additional secondary endpoints were progression-free survival, one-year survival rate, progression-free survival at six months, duration of response, and rate of patients with treatment emergent adverse events.

Novocure announced that Japan's Ministry of Health, Labour and Welfare approved reimbursement for Optune Lua through the country's National Health Insurance coverage. Optune Lua is approved in Japan for concurrent use with PD-1/PD-L1 inhibitors in adult patients with unresectable advanced/recurrent NSCLC who progressed on or after platinum-based chemotherapy.

Reports Q4 revenue $174.35M, consensus $173.36M. "In 2025, a record number of patients received treatment with Novocure's Tumor Treating Fields therapy, a milestone that reflects our growth and commitment to advancing the treatment of cancer with our technology," said Frank Leonard, CEO, Novocure. "This momentum continues in 2026 with the U.S. FDA approval of Optune Pax for pancreatic cancer, an achievement we are incredibly proud of given the exceptional challenge of developing treatment for this disease. We are well-positioned to continue to drive our patient-forward mission while prioritizing our goal of achieving profitability."

Sees FY26 adjusted EBITDA loss of $20M to flat. The company said, "This guidance assumes full-year low-to-mid single digit net revenue growth from Optune Gio, net revenue contribution from Optune Lua and Optune Pax, collectively, between $15 million to $25 million, mid-70's percent gross margin, and foreign exchange rates as of December 31, 2025."